Colomid: Midkine as a predictive marker in colorectal cancer
Not Applicable
Completed
- Conditions
- Advanced or metastatic colorectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)
- Registration Number
- ACTRN12613000111774
- Lead Sponsor
- Calvary Mater Newcastle Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Ability to give informed consent
Metastatic or locally advanced colorectal cancer
Starting on a new course of chemotherapy for colorectal cancer
Adequate organ function to permit chemotherapy to be given
Life expectancy of more than 3 months
Measurable or non-measurable lesions
Ability to comply with study procedures
Exclusion Criteria
Past history of malignancy, other than non-melanoma skin cancers
Current active inflammatory, autoimmune or infective process
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method